Powder: -20°C for 3 years | In solvent: -80°C for 1 year
(Rac)-JBJ-04-125-02 (JBJ-04-125-02) 是 JBJ-04-125-02 的消旋体,是选择性突变,可口服的 EGFR 变构抑制剂,对EGFRL858R/T790M 的IC50为 0.26 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 847 | 现货 | ||
5 mg | ¥ 2,280 | 现货 | ||
10 mg | ¥ 3,660 | 现货 | ||
25 mg | ¥ 5,890 | 现货 | ||
50 mg | ¥ 8,190 | 现货 | ||
100 mg | ¥ 10,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,730 | 现货 |
产品描述 | (Rac)-JBJ-04-125-02 (JBJ-04-125-02) is effective as a single agent in both in vitro and in vivo models of EGFR-mutant lung cancer. |
靶点活性 | EGFR:0.26 nM |
体外活性 | (Rac)-JBJ-04-125-02 is the racemate of JBJ-04-125-02. JBJ-04-125-02 is a potent, mutant-selective, allosteric and orally active EGFR inhibitor with an IC50 of 0.26 nM for EGFRL858R/T790M[1]. |
体内活性 | The combination of osimertinib and JBJ-04-125-02 is a significantly more effective treatment approach than either agent alone[1]. |
动物实验 | Ba/F3, H1975, H3255GR and H3255DR cells were treated with increasing concentrations of inhibitors for 72 hours and growth or the inhibition of growth was assessed by MTS assay according to previously established methods. |
别名 | JBJ-04-125-02 |
分子量 | 543.61 |
分子式 | C29H26FN5O3S |
CAS No. | 2140807-05-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (101.17 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.8396 mL | 9.1978 mL | 18.3955 mL | 45.9889 mL |
5 mM | 0.3679 mL | 1.8396 mL | 3.6791 mL | 9.1978 mL | |
10 mM | 0.184 mL | 0.9198 mL | 1.8396 mL | 4.5989 mL | |
20 mM | 0.092 mL | 0.4599 mL | 0.9198 mL | 2.2994 mL | |
50 mM | 0.0368 mL | 0.184 mL | 0.3679 mL | 0.9198 mL | |
100 mM | 0.0184 mL | 0.092 mL | 0.184 mL | 0.4599 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
(Rac)-JBJ-04-125-02 2140807-05-0 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR Allosteric anti-proliferation HER1 inhibit JBJ-04-125-02 ErbB-1 (Rac)JBJ0412502 Inhibitor racemate Epidermal growth factor receptor anti-tumor (Rac) JBJ 04 125 02 T790M-mutant inhibitor